TP53 and melanoma: These results, along with our previous observations that DNA-damaging agents such as cisplatin and adriamycin that increased the levels of p53 but did not up-regulate TRAL-R2 in melanoma cells [[32], & data not shown], suggest that p53 may not be functionally active in melanoma cells in regard to regulation of TRAIL-R2 expression.